Trial Profile
Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2018
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Sorafenib (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- 26 Nov 2018 Status changed from recruiting to completed.
- 15 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 18 Nov 2014 New trial record